Abstract
Background Mitochondrial DNA (mtDNA) content might be involved in the risk of cardiovascular disease. We aimed to investigate the association of mtDNA copy number (mtDNA-CN), as a proxy of mtDNA content, and coronary artery disease (CAD) and heart failure (HF) using multivariable adjusted and Mendelian Randomizations (MR) analyses.
Methods Multivariable-adjusted analyses were conducted using Cox-proportional hazard models in 273,619 unrelated European descendants from UK Biobank (UKB). MtDNA-CN in peripheral blood cells was computed based on the weighted intensities of the mitochondrial genome probes. For the two-sample MR analyses, single nucleotide polymorphisms (SNPs) associated with mtDNA-CN were retrieved from genome-wide association studies in UKB. SNP-outcome associations were obtained for CAD from CARDIoGRAMplusC4D, UKB and FinnGen, comprising 902,538 participants (134,759 cases), and for HF from the HERMES consortium and FinnGen, collectively having data on 1,195,531 participants (70,706 cases). MR analyses were performed per database and results were subsequently meta analyzed using fixed-effects models per study.
Results During a median follow-up of 11.8 years, participants in the lowest quintile of mtDNA-CN had higher risk for CAD (hazard ratio [95% CI]: 1.08 [1.03, 1.14]) and HF (hazard ratio [95% CI]: 1.15 [1.05, 1.24]) compared to those in the highest quintile. In MR analyses, the pooled odds ratios of genetically predicted per one-SD decrease in mtDNA were 1.16 (95% CI: 1.05, 1.27) for CAD and 1.00 (95% CI: 0.90, 1.10) for HF, respectively.
Conclusion Our findings support a possible causal role of lower mtDNA-CN in higher CAD risk, but not in higher HF risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the VELUX Stiftung (grant number 1156) (to Drs. van Heemst and Noordam). Ms. Luo was supported by the China Scholarship Counsel (No. 201808500155). Dr. Noordam was supported by an innovation grant from the Dutch Heart Foundation (grant number 2019T103).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UKB study was approved by the North-West Multi-center Research Ethics Committee (MREC). Ethical approvals for other publically available data were obtained separately by the original study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data we used are either from publically available sources as indicated in the manuscript, or from the UKB, which is open to all researches at reasonable request.
